OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 134
Showing 26-50 of 134 citing articles:
Discovery of reactive peptide inhibitors of human papillomavirus oncoprotein E6
Xiyun Ye, Peiyuan Zhang, Jason Tao, et al.
Chemical Science (2023) Vol. 14, Iss. 44, pp. 12484-12497
Open Access | Times Cited: 15
Xiyun Ye, Peiyuan Zhang, Jason Tao, et al.
Chemical Science (2023) Vol. 14, Iss. 44, pp. 12484-12497
Open Access | Times Cited: 15
Vinorelbine causes a neuropathic pain-like state in mice via STING and MNK1 signaling associated with type I interferon induction
Úrzula Franco‐Enzástiga, Keerthana Natarajan, Eric T. David, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108808-108808
Open Access | Times Cited: 5
Úrzula Franco‐Enzástiga, Keerthana Natarajan, Eric T. David, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108808-108808
Open Access | Times Cited: 5
Efficacy of topical agents in oral mucositis prevention: Systematic review and network meta‐analysis
Martina Coppini, Vito Carlo Alberto Caponio, Rodolfo Mauceri, et al.
Oral Diseases (2024) Vol. 30, Iss. 7, pp. 4126-4144
Open Access | Times Cited: 5
Martina Coppini, Vito Carlo Alberto Caponio, Rodolfo Mauceri, et al.
Oral Diseases (2024) Vol. 30, Iss. 7, pp. 4126-4144
Open Access | Times Cited: 5
Synergistic targeting of TrxR1 and ATM/AKT pathway in human colon cancer cells
Xin Shen, Yiqun Xia, Hui Jing Lu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116507-116507
Open Access | Times Cited: 4
Xin Shen, Yiqun Xia, Hui Jing Lu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116507-116507
Open Access | Times Cited: 4
Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs
Gregorio Peron, Andrea Mastinu, Sheila I. Peña‐Corona, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117047-117047
Closed Access | Times Cited: 4
Gregorio Peron, Andrea Mastinu, Sheila I. Peña‐Corona, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117047-117047
Closed Access | Times Cited: 4
Exploring novel therapeutic targets in small bowel adenocarcinoma: insights from claudin 18.2, nectin-4, and HER3 expression analysis
Hiroyuki Fujii, Hirokazu Shoji, Hidekazu Hirano, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104098-104098
Open Access
Hiroyuki Fujii, Hirokazu Shoji, Hidekazu Hirano, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104098-104098
Open Access
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model
Zimin Zhang, Mingyang Zhu, Weiwei Jiang
Clinical and Translational Science (2025) Vol. 18, Iss. 1
Open Access
Zimin Zhang, Mingyang Zhu, Weiwei Jiang
Clinical and Translational Science (2025) Vol. 18, Iss. 1
Open Access
Multi-Omics Analysis Reveals Immune Infiltration and Clinical Significance of Phosphorylation Modification Enzymes in Lung Adenocarcinoma
Deyu Long, Yanheng Ding, Peng Wang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1066-1066
Open Access
Deyu Long, Yanheng Ding, Peng Wang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1066-1066
Open Access
Rationally Designed Cell Membrane Biomimetic Biosensing Platform for the Binding Analysis of Drugs with Intracellular Kinase Domain of Epidermal Growth Factor Receptor
Xia Liu, Quan Feng, Qi Hu, et al.
Analytical Chemistry (2025)
Closed Access
Xia Liu, Quan Feng, Qi Hu, et al.
Analytical Chemistry (2025)
Closed Access
Review of studies evaluating the effectiveness of risk minimization measures for oncology medicinal products registered in the european medicines agency (HMA-EMA) catalogue: findings and lessons learned
Jorge Monteiro, Diogo Fraxino de Almeida, João Paulo Fernandes, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
Jorge Monteiro, Diogo Fraxino de Almeida, João Paulo Fernandes, et al.
Expert Opinion on Drug Safety (2025)
Closed Access
MARVELD1 inhibits Neuro2a cell migration and tumorigenesis via regulating the transcriptional coactivators and protein methylation
Weizhe Liu, Yucui Dong, Ruiying Guo, et al.
Bulletin du Cancer (2025)
Closed Access
Weizhe Liu, Yucui Dong, Ruiying Guo, et al.
Bulletin du Cancer (2025)
Closed Access
Leading prodrug strategies for targeted and specific release
Rupa Bargakshatriya, Sumit Kumar Pramanik
Future Medicinal Chemistry (2025), pp. 1-4
Closed Access
Rupa Bargakshatriya, Sumit Kumar Pramanik
Future Medicinal Chemistry (2025), pp. 1-4
Closed Access
A review of recent advances in anticancer activity and SAR of pyrazole derivatives
Heba A. Hofny, Mamdouh F. A. Mohamed, Heba A. Hassan, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 3
Closed Access
Heba A. Hofny, Mamdouh F. A. Mohamed, Heba A. Hassan, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 3
Closed Access
Overcoming Financial and Access Barriers in Global Cancer Care With Low-Dose Immunotherapy: A Systematic Review
Celine Hoyek, Binbin Zheng-Lin, Jennah J. Bauernfeind, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Celine Hoyek, Binbin Zheng-Lin, Jennah J. Bauernfeind, et al.
JCO Global Oncology (2025), Iss. 11
Open Access
Oncobiomics: Leveraging Microbiome Translational Research in Immuno-Oncology for Clinical-Practice Changes
Carolina Alves Costa Silva, Andrew A. Almonte, Laurence Zitvogel
Biomolecules (2025) Vol. 15, Iss. 4, pp. 504-504
Open Access
Carolina Alves Costa Silva, Andrew A. Almonte, Laurence Zitvogel
Biomolecules (2025) Vol. 15, Iss. 4, pp. 504-504
Open Access
Comparative Analysis of Clinical Characteristics of Patients with Malignant Solid Tumors Treated with and without Immunocheckpoint Inhibitors after COIVD-19 Infection
科宇 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 1251-1258
Closed Access
科宇 张
Advances in Clinical Medicine (2025) Vol. 15, Iss. 04, pp. 1251-1258
Closed Access
Emerging trends and thematic evolution of immunotherapy for glioma based on the top 100 cited articles
Yan Zhou, Min Liu, Xing Huang, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 4
Yan Zhou, Min Liu, Xing Huang, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access | Times Cited: 4
Camptothesome-based combination nanotherapeutic regimen for improved colorectal cancer immunochemotherapy
Zhiren Wang, Wenpan Li, Yanhao Jiang, et al.
Biomaterials (2024) Vol. 306, pp. 122477-122477
Open Access | Times Cited: 4
Zhiren Wang, Wenpan Li, Yanhao Jiang, et al.
Biomaterials (2024) Vol. 306, pp. 122477-122477
Open Access | Times Cited: 4
A review of Brucea javanica: metabolites, pharmacology and clinical application
Jing Chen, Dongke Yu, Xinyu Li, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 4
Jing Chen, Dongke Yu, Xinyu Li, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 4
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 4
Xuwen Lin, Mei Xie, Jie Yao, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 3
Open Access | Times Cited: 4
Metabolic heterogeneity in tumor microenvironment – A novel landmark for immunotherapy
Chen Chen, Peng Han, Yanping Qing
Autoimmunity Reviews (2024) Vol. 23, Iss. 6, pp. 103579-103579
Closed Access | Times Cited: 4
Chen Chen, Peng Han, Yanping Qing
Autoimmunity Reviews (2024) Vol. 23, Iss. 6, pp. 103579-103579
Closed Access | Times Cited: 4
Challenges in interpreting survival metrics in clinical trials: the utility of restricted mean survival analyses
Itamar Averbuch, Avital Bareket‐Samish, Daniel A. Goldstein, et al.
International Journal of Radiation Oncology*Biology*Physics (2025)
Open Access
Itamar Averbuch, Avital Bareket‐Samish, Daniel A. Goldstein, et al.
International Journal of Radiation Oncology*Biology*Physics (2025)
Open Access
A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2686-2701
Open Access | Times Cited: 10
Amr El Zawily, Frederick S. Vizeacoumar, Renuka Dahiya, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 14, pp. 2686-2701
Open Access | Times Cited: 10
Noah Earland, Wubing Zhang, Abul Usmani, et al.
Immunological Reviews (2023) Vol. 318, Iss. 1, pp. 96-109
Closed Access | Times Cited: 9
Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials
Zhishan Zhang, Qunxiong Pan, Mingdong Lu, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102156-102156
Open Access | Times Cited: 9
Zhishan Zhang, Qunxiong Pan, Mingdong Lu, et al.
EClinicalMedicine (2023) Vol. 63, pp. 102156-102156
Open Access | Times Cited: 9
